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Abstract 16 
 17 
Introduction: The pharmacokinetic properties of anti-infective drugs are a determinant part of 18 
treatment success. Pathogen replication is inhibited if adequate drug levels are achieved in 19 
target sites, whereas excessive drug concentrations linked to toxicity are to be avoided. Anti-20 
infective distribution can be predicted by integrating in vitro drug properties and 21 
mathematical descriptions of human anatomy in physiologically based pharmacokinetic 22 
models. This method reduces the need for animal and human studies and is used increasingly 23 
in drug development and simulation of clinical scenario such as, for instance, drug-drug 24 
interactions, dose optimisation, novel formulations and pharmacokinetics in special 25 
populations.  26 
Areas covered: We have assessed the relevance of physiologically based pharmacokinetic 27 
modelling in the anti-infective research field, giving an overview of mechanisms involved in 28 
model design, and have suggested strategies for future applications of physiologically based 29 
pharmacokinetic models. 30 
Expert opinion: Physiologically based pharmacokinetic modelling provides a powerful tool in 31 
anti-infective optimisation, and there is now no doubt that both industry and regulatory 32 
bodies have recognised the importance of this technology. It should be acknowledged, 33 
however, that major challenges remain to be addressed and that information detailing disease 34 
group physiology and anti-infective pharmacodynamics is required if a personalised medicine 35 
approach is to be achieved. 36 
 37 
 38 
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1. Introduction  39 
 40 
1.1 The importance of anti-infective pharmacokinetics 41 
Favourable pharmacokinetic properties of anti-infective drugs are essential for treatment 42 
success, as these drugs require access to the pathogen to elicit an effect. In recent years, 43 
numerous studies have clarified the relevance of anti-infective pharmacokinetics (PK) for 44 
successful treatment and identified predictors of exposure in different populations of patients. 45 
In addition, anti-infective PK optimisation is an essential component for reducing the risk of 46 
drug-related toxicity for the host. However, in many cases a clear relationship has not been 47 
established between host toxicity and exposure. A complication in determining optimal 48 
exposure of anti-infectives is the often diverse pharmacokinetic-pharmacodynamic (PK-PD) 49 
relationship observed among drug classes. For example, β-lactams need to occupy the 50 
majority of binding sites in the bacteria before any real antibacterial effect is achieved and, 51 
subsequently, there is not a direct relationship between exposure and effect in patients in this 52 
case1. 53 
Physiologically based pharmacokinetic modelling is a bottom up technique which simulates 54 
the pharmacokinetics using in vitro drug data (i.e. physicochemical characteristics, intrinsic 55 
clearance, permeability) through a mathematical description of drug distribution. PBPK exists 56 
as a powerful tool in the development of future treatments and pharmacokinetic optimisation. 57 
This review investigates the strategy behind PBPK modelling, with particular emphasis on 58 
anti-infective pharmacokinetics. Specific clinical scenarios are also discussed, where patient 59 
demographics, genetics, drug-drug interactions (DDIs) and anti-infective exposure are 60 
considered in model development and treatment outcomes. 61 
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 62 
1.2 Physiologically based pharmacokinetic models  63 
The PK of anti-infective agents results from a complex interplay of molecular and 64 
physiological processes in tissues mediated by a large variety of proteins. The in vivo 65 
disposition of a drug can be divided in three main phases: absorption, distribution in tissues 66 
and organs, and metabolism/elimination (ADME). An increasing number of studies are 67 
focusing on the identification of proteins involved in these ADME processes and their 68 
quantitative description is currently available.2, 3. This broad base of knowledge is essential 69 
for a successful prediction of PK through mathematical modelling. Mathematical equations 70 
are being used to describe processes influencing PK, such as tablet dissolution rate following 71 
administration, renal clearance, actions of drug transporters, gastrointestinal pH, phase I and 72 
phase II metabolism, as well as numerous other biological processes. Interestingly, all these 73 
processes can be described in a dynamic way to reflect their evolution over time4-6. In PBPK 74 
models, the human body is divided into anatomically meaningful compartments which 75 
integrate specific properties of a given organ (i.e. blood flow, organ mass, permeation limits, 76 
percentage fat) with drug characteristics which creates a structural model reflecting the 77 
anatomical arrangement of the tissues connected by perfusing blood. An example of a typical 78 
PBPK model is represented in Figure 1. The in vitro intrinsic metabolism rate of a drug is 79 
usually quantified using tissue-derived microsomes or cell lines expressing relevant 80 
metabolic enzymes, and this information is subsequently scaled up to determine whole organ 81 
clearance by considering local enzyme expression and other tissue-specific factors. 82 
Additional variables, specifically the blood flow rate to the liver and the extent to which the 83 
drug binds to plasma protein, are also considered when deriving blood clearance. The 84 
prediction of renal elimination can present issues due to the presence of several distinct 85 
processes in renal drug elimination. Drug excretion in the kidney consists of glomerular 86 
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filtration (passive process), tubular reabsorption (both passive and transporter mediated 87 
process) and tubular secretion (transporter mediated process). Recently, in silico modelling 88 
approaches have been developed to generate a prediction of renal clearance based on 89 
physicochemical properties7. 90 
Importantly, all the aforementioned ADME processes are highly variable between 91 
individuals. PBPK modelling overcomes this, as virtual patients can be simulated considering 92 
specific anatomical and physiological factors in populations. Changes in organ size and other 93 
anatomical characteristics have indeed been correlated with demographic variables in 94 
anthropometric studies8-10, and multifactorial equations have been defined to generate 95 
anatomical and physiological parameters and their inter-individual variability. This set of 96 
equations constitutes an essential component of PBPK approaches in order to correctly 97 
capture the variability that is present in the population of interest. Through this approach it is 98 
possible to generate a virtual (but realistic) description of anatomical characteristics of 99 
patients and therefore obtain a representative evaluation of the variability in populations.  100 
This characteristic, as well as numerous others, makes PBPK modelling particularly suitable 101 
for the discovery and optimisation of anti-infective agents, which often require access to 102 
specific infected tissues or target cells to elicit an effect. As an example, antiretroviral drugs 103 
need access to immune cells, the primary target of the human immunodeficiency virus (HIV). 104 
Additionally, non-linear concentration-efficacy relationships have been reported for 105 
ciprofloxacin11 and voriconazole12, and the non-linear protein binding observed with 106 
molecules such as ceftriaxone13, cefazolin14, cefonicid15, ertapenem16 and tigecycline17 could 107 
be modelled by providing the mathematical expression of the change in protein binding with 108 
varying concentrations of the drug in plasma. 109 
 110 
 111 
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2. Clinical scenarios and therapy optimisation  112 
Patient demographics, genetics, anti-infective exposure, status of the immune system, 113 
pathogen characteristics, and adherence may each affect the efficacy of anti-infective therapy. 114 
PBPK modelling can simulate clinical scenarios to assess the impact of such factors on the 115 
PK of anti-infective drugs with the ultimate goal to optimize therapy. The use of PBPK 116 
modelling to simulate clinical scenarios in relation to special populations, genetics, drug 117 
interactions, formulations and penetration in tissues is discussed thereafter (Figure 2).  118 
 119 
2.1 Special populations  120 
Most pharmacokinetic clinical trials performed during the drug development processes are 121 
based on the inclusion of healthy volunteers and often exclude subjects with specific 122 
conditions and characteristics. Subpopulations of patients such as pregnant women, children 123 
and infants, cirrhotic and HIV/HCV co-infected patients, elderly, obese and malnourished 124 
individuals have been largely underrepresented in clinical trials. As a consequence, the 125 
optimization of therapies is particularly challenging in these special populations due to the 126 
paucity of relevant pharmacokinetic data. The pharmacokinetics of certain drugs is known to 127 
be substantially affected by anatomical and physiological characteristics of special 128 
populations, as summarised in Table 1. Alterations in pharmacokinetic characteristics of anti-129 
infectives are have been identified in special populations, such as the increased plasma 130 
concentrations observed in paediatric patients administered with cyclosporine, and the 131 
increased renal clearance of amoxicillin observed in pregnant women18-20. Through the 132 
incorporation of anatomical characteristics of special populations, PBPK modelling can 133 
predict anti-infective distribution in these subpopulations of interest and thus enables a better 134 
understanding of the relationship between anatomical factors and pharmacokinetics.  135 
7 
 
The aging process is characterised by progressive changes in several anthropometric 136 
variables and changes in the expression of key ADME enzymes and transporters21. Several 137 
classes of drugs, including anti-infectives, are more frequently prescribed to elderly 138 
compared to younger individuals. Consequently, the management of therapies in older 139 
patients is further complicated by a complex polypharmacy which increases the risk of 140 
potential DDIs, toxicity and loss of efficacy22. A comprehensive database describing the 141 
effect of age on relevant factors for drug distribution has been recently published and 142 
represents a valuable tool to define a realistic set of parameters for PBPK simulations in older 143 
patients23. A first example of PBPK modelling for dose finding and clinical trials in elderly 144 
populations has been recently presented24.  145 
The optimisation of dosing strategies in paediatric patients is complicated by several ethical 146 
and pharmacological factors but also by the absence of optimal formulations. Dose finding 147 
studies are rarely performed in this population; often the selection of therapeutic doses for 148 
children and infants is based on empirical scaling from adults where the dose is adjustment 149 
for body weight. However, the ontogeny of metabolic enzyme and transporter expression is 150 
not linearly correlated with age and, consequently, a direct dose scaling for children does not 151 
represent an optimal strategy in most cases. Moreover, physiological changes are more 152 
prominent for infants, further complicating the selection of doses in this frail special 153 
population25. The description of metabolic enzyme ontogeny in the different stages of 154 
childhood is available and has been included in PBPK approaches for simulation of 155 
pharmacokinetics in paediatric patients26. The optimisation of anti-infective therapies in 156 
infants and children could greatly benefit from a broader application of PBPK models, 157 
considering the clinical relevance of effective pharmacological tools to treat infections in 158 
paediatric patients. Although treatment of paediatric HIV patients results in several short and 159 
long term clinical benefits, available clinical options are limited. PBPK modelling has been 160 
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effectively applied in the simulation of antiretroviral pharmacokinetics in children, 161 
hypothesising dose optimisation based on genetic factors and weight27. 162 
Obesity is characterised by numerous anatomical changes that alter anti-infectives disposition 163 
with potential downstream effects on drug efficacy and toxicity. The risk of nosocomial 164 
infections is higher in this subpopulation of patients and can be associated with the 165 
development of resistances due to suboptimal anti-infective dosing28. The changes in organ 166 
composition, tissue volume, cytochrome P450 expression and blood flow have been 167 
mathematically described and successfully included in PBPK simulations suggesting dose 168 
adjustments and identifying patients with an higher risk of sub-therapeutic concentrations29, 169 
30. For instance, the antiretroviral efavirenz, when used at the standard 600 mg once daily 170 
dose, was shown not to achieve adequate plasma exposure in obese patients. 171 
An additional special population that require dose adjustment and optimization of therapeutic 172 
strategies is pregnant women. During pregnancy, several physiological changes are occurring 173 
and the correct dosing of anti-infectives acquires extreme relevance considering the potential 174 
exposure of the foetus to life-threatening infections and/or drug related toxicities. The first 175 
PBPK model simulating drug distribution in pregnant women and foetus was published in 176 
1994 and subsequent studies have followed31-33. This approach has the potential to define 177 
optimal therapeutic options for pregnant women infected by pathogens. 178 
In several ways, disease groups can themselves be treated as special populations. An 179 
important factor in the optimisation of anti-infectives is the understanding of how the 180 
progression of disease affects the physiological characteristics of the patient important for 181 
drug disposition. Due to the heavy nvolvement of the liver in drug metabolism and 182 
elimination, diseases which alter the physiological state of the liver, such as viral hepatitis, 183 
have been investigated for their effect on liver-based drug metabolism enzymes and 184 
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transporters. The expression levels of numerous cytochrome P450 (CYP) and phase II 185 
enzymes (CYP1A2, CYP2E1, CYP2D6, UGT1A) and transporters (ABCB1, ABCC2, 186 
ABCC3, SLC10A1, SLC22A1) in hepatitis C patients were shown to decrease as the severity 187 
of liver fibrosis, or fibrosis stage (F), increased34. Other studies have also concluded that 188 
hepatitis, particularly in cases with more severe liver damage, can alter the expression level 189 
of metabolism enzymes, and drug transporters35-39. Not all cases show reduced expression, 190 
with a recent study showing the up-regulation of transporter ABCC4 and enzyme CYP1B1 in 191 
patients with end-stage liver disease40. Additionally, nuclear receptors which are involved in 192 
the regulation of liver enzyme and transporter expression, such as the aryl hydrocarbon 193 
receptor (Ahr), the constitutive androstane receptor (CAR) and the pregnane X receptor 194 
(PXR), show reduced expression in hepatitis C patients with fibrosis development34. The 195 
pharmacokinetic parameters of ribavirin have been assessed in hepatitis C patients using 196 
population pharmacokinetic modelling. Although no PBPK models have been created which 197 
simulate the reduced abundance of enzymes and transporters in hepatitis C patients 198 
displaying various levels of liver damage, this would be achievable by adjusting the amount 199 
of enzyme/transporter expressed per mg of liver. The PBPK models created could then be 200 
used to predict the impact of the liver damage on drug clearance rate. An additional factor to 201 
consider adjusting would be hepatic blood flow, an important factor in the determination of 202 
drug clearance and which reduces in patients with chronic hepatitis C infection41. 203 
 204 
 205 
 206 
 207 
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2.2 Genetics  208 
The expression and activity of metabolic enzymes and transporters involved in ADME are 209 
influenced by genetic variants which can have a relevant downstream effect on PK. Phase I 210 
and Phase II metabolic enzymes have been investigated using in vitro and clinical 211 
pharmacogenetic studies and a broad knowledge describing the correlation between genetics 212 
and PK is currently available 3. Numerous anti-infectives are metabolised or eliminated by 213 
polymorphic enzymes and therefore pharmacogenetics may influence efficacy and toxicity in 214 
patients.  215 
The influence of genetic variables on anti-infective PK can be predicted through PBPK 216 
modelling. In vitro systems can be utilised to clarify how polymorphisms alter expression and 217 
activity of transporters and drug metabolizing enzymes, and these investigations can be 218 
included in PBPK models. This approach has been applied to clarify the impact of CYP2B6 219 
genetics on efavirenz pharmacokinetics and to help hypothesise potential pharmacogenetics-220 
driven dose adjustment strategies42, 43. For instance, it was demonstrated that the dose amount 221 
of efavirenz, which is normally administered at 600 mg once-daily, can be decreased to 400 222 
mg once-daily in HIV-infected individuals carrying the CYP2B6 516GT genotype 223 
(heterozygous mutation associated with a lower metabolizing activity of CYP2B6) and to 200 224 
mg once daily in carriers of 516TT genotype (homozygous mutation) without compromising 225 
HIV virological suppression. Another disease area that could benefit from an application of 226 
PBPK modelling is fungal infections. Voriconazole is an antifungal with a broad spectrum of 227 
activity and is the treatment of choice for invasive aspergillosis and oesophageal candidiasis. 228 
The pharmacokinetics of this drug is highly variable between patients and this can cause 229 
suboptimal exposure or concentration dependent toxicity44. Voriconazole is mainly 230 
metabolised by CYP2C19, which is characterised by different genetic variants that can 231 
influence the activity of the enzyme. The CYP2C19*2 and *3 alleles have been correlated 232 
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with a “poor metaboliser” phenotype and other genotypes, such as CYP2C19*17, have been 233 
associated with increased enzymatic activity45, 46. Dose adjustment strategies for voriconazole 234 
may constitute an effective intervention to limit sub-optimal pharmacokinetics and PBPK 235 
models could support the selection of potential pharmacogenetics-driven dose 236 
individualisation strategies. 237 
 238 
2.3 Drug-drug interactions 239 
Pharmacokinetic DDIs occur when the exposure of a drug (victim) is impaired by the co-240 
administration of a drug inhibiting or inducing (perpetrator) the metabolic pathway 241 
responsible for the elimination of the victim drug. DDIs are of major concern in the clinical 242 
practice as they may impair drug efficacy or precipitate toxicity and, in case of life-243 
threatening adverse events, may contribute to the withdrawal of a drug from the market47. 244 
Thus, the evaluation of a drug’s potential for DDIs has become essential during the process of 245 
preclinical drug development. Regulatory guidelines recommend that the initial risk 246 
assessment for metabolic DDIs is done using in vitro studies to investigate whether the 247 
investigational drug inhibits or induces the cytochrome P450 (CYP) enzymes48, 49. In vitro 248 
data are subsequently integrated in mathematical models to evaluate the in vivo risk of 249 
inhibition or induction and thereby the need for conducting clinical DDI studies50.  250 
In the recent years, approaches to DDI prediction have evolved from the use of single 251 
equations to the use of software tools which integrate physiological and drug parameters 252 
together with a dynamic model to describe pharmacokinetics in humans51. Such PBPK 253 
models incorporate the temporal changes in the concentration of the perpetrator and victim 254 
drugs and thus allow simulations of concentration-time profiles for the inhibition or 255 
induction52-55. Furthermore, the PBPK approach enables the user to assess the effect of 256 
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various parameters (i.e. dosing regimen, dose staggering, concurrent inhibition and induction 257 
of multiple CYPs) on the magnitude of DDIs. Thus, this approach provides a more 258 
comprehensive and precise report of DDIs56, 57. Finally, the inclusion of the inter-individual 259 
variability in CYP expression arising from genetic, demographic or pathophysiological 260 
differences assists in defining the extent of the interaction magnitude at the extremes of the 261 
population58. The regulatory guidelines were recently updated to include the use of PBPK 262 
modelling at different stages of drug development with the purpose of assessing the potential 263 
for DDIs (early stage), to update initial PBPK models once more when in vivo data are 264 
available (late stage) and to inform the design of in vivo DDI studies (at all stages)49. 265 
Given their well characterized effects on CYP3A, anti-infective agents have often been used 266 
in PBPK models. Such models aim to elucidate the mechanism and time course of DDIs 267 
observed in clinical studies59-61, to build mechanistic models54, 55 or to inform the design of 268 
clinical drug interaction studies (i.e. determination of the timing of administration of the 269 
perpetrator drug to achieve the maximal inhibitory or inductive effect)57, 62-64. For instance, 270 
ketoconazole, a reversible inhibitor of CYP3A and P-glycoprotein, has been used to assess 271 
the interaction with a tyrosine kinase inhibitor. The magnitude of the interaction was first 272 
determined in a clinical study in healthy volunteers who received the investigational drug 273 
alone and in presence of ketoconazole. The simulation of the DDIs using a PBPK model 274 
showed that the inhibition of P-glycoprotein by ketoconazole must be taken into 275 
consideration, in addition to CYP3A inhibition, to fully explain the magnitude of the 276 
observed DDI61. Time-dependent inhibitors such as clarithromycin and telithromycin have 277 
been used to build mechanistic models able to simulate their non-linear pharmacokinetics and 278 
the related effect on the clearance of the victim drug midazolam54, 55. The elaboration of such 279 
mechanistic models is of interest as they may provide a framework for the prediction of other 280 
time-dependent DDIs. Finally, ketoconazole and rifampicin, a potent inducer of CYP3A, 281 
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have been used in PBPK models to inform about the maximal inhibitory and inductive effect 282 
of CYP3A, respectively, and thereby inform the design of DDI studies57, 62. For instance, 283 
Zhao et al. showed that a single dose of ketoconazole resulted in maximal inhibition for 284 
CYP3A substrates with short half-life and low bioavailability. Conversely, multiple doses of 285 
ketoconazole were required to achieve maximal inhibition for CYP3A substrates with long 286 
half-life. Whereas, a more recent study seems to indicate that multiple doses of ketoconazole 287 
are needed to reach maximal inhibition independently of the victim drug half-life63. Baneyx 288 
et al. showed that the maximal inductive effect was achieved with rifampicin pretreatment for 289 
five days and the administration of the victim drug at least two hours after the last rifampicin 290 
dose. Collectively, such simulations are important as a suboptimal inhibition or induction can 291 
lead to the underestimation of the DDI magnitude with a given CYP3A substrate. Rifampicin 292 
has also been used to evaluate the interplay between CYP3A4 and the hepatic uptake 293 
transporter OATP1B1 and its impact on repaglinide exposure65. The PBPK modelling 294 
showed that the opposite effects of rifampicin on CYP3A4 (induction) and OATP1B1 295 
(inhibition) impacted repaglinide exposure differently depending on the timing of 296 
administration of the two drugs. CYP3A4 induction and OATP1B1 inhibition were apparent 297 
when both drugs were administered in temporal proximity, whereas CYP3A4 induction was 298 
more pronounced when the drugs were administered >12 h apart. Thus, mechanistic models 299 
should also take into account transporters in order to accurately predict DDIs, especially for 300 
drugs such as repaglinide whose systemic clearance is impacted by both the hepatic uptake 301 
and the metabolism.  302 
In the field of DDI prediction, PBPK models have been useful to simulate virtual clinical 303 
studies in order to characterize DDIs for drug combinations used in the clinical practice but 304 
for which limited clinical data are available. For instance, PBPK models simulating virtual 305 
clinical trials were applied to predict the magnitude of DDIs between efavirenz or boosted 306 
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protease inhibitors and commonly prescribed antidepressants56. These antiretroviral drugs are 307 
characterized by mixed inhibitory/inductive effects on CYPs. The approach consisted to 308 
initially build mechanistic models, and to subsequently validate their robustness by 309 
comparing the magnitude of simulated DDIs using classical probe drugs to that observed in 310 
clinical studies. These models were then applied to simulate the magnitude of DDI that would 311 
be observed if the investigated antiretroviral drugs were given in individuals during 14 days 312 
followed by 8 days of concomitant administration with a given antidepressant. By taking into 313 
account the concurrent inhibitory and inductive effect of antiretroviral drugs on CYPs, the 314 
PBPK simulation showed that the magnitude of DDIs with antidepressants was overall weak 315 
to moderate. The modest magnitude has been attributed to the fact that antidepressants are 316 
substrates of multiple isoforms and thus metabolism can still occur through CYP that are 317 
weakly impacted by efavirenz or boosted protease inhibitors.  318 
Simulations of virtual clinical trials have not only been used to quantify a DDI but also to 319 
determine the dose adjustment to overcome a given interaction66. For instance, antimalarial 320 
drugs are often used concomitantly with antiretroviral drugs in African countries to treat co-321 
infected patients. Such drug combinations are difficult to handle as antimalarial drugs are 322 
susceptible to DDIs whereas a suboptimal drug exposure can lead to treatment failure and 323 
drug resistance. A PBPK model was used to simulate the magnitude of the DDI between 324 
efavirenz (600 mg once daily) and artemether (80 mg twice daily) in virtual subjects. 325 
Efavirenz was shown to reduce artemether area under the curve (AUC) by 80%, tripling the 326 
dose of artemether enabled to compensate efavirenz inductive effect. Simulations in a virtual 327 
population were also performed to evaluate the magnitude of the DDI between rifampicin and 328 
efavirenz based on the body weight and CYP2B6 genotype. This study aimed to define the 329 
weight cut-off requiring an increase in efavirenz dose to counteract the interaction with 330 
rifampicin. The results showed that an increase in efavirenz dose to 800 mg was appropriate 331 
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only in individuals with a body weight over 50 kg67. Finally, simulations in virtual 332 
individuals were done to provide recommendations on how to switch antifungal drugs given 333 
the presence of residual CYP inhibition. The switch from fluconazole (CYP2C19 inhibitor) to 334 
voriconazole (substrate of CYP2C19) was simulated using various lag times during 335 
treatment. This study showed that fluconazole would continue to have an inhibitory effect on 336 
voriconazole for at least 24 hours after its discontinuation68. Collectively, these studies show 337 
that the use of PBPK modelling to simulate clinical scenarios has the potential to provide 338 
answers to specific clinical questions which may be difficult to study in patients or for which 339 
data are lacking. Some examples of clinically relevant scenarios involving anti-infective 340 
drugs for which PBPK modelling could potentially help optimizing therapy include:  341 
- The simulation of the magnitude of DDIs between antiretroviral agents and direct acting 342 
antiviral agents for hepatitis C virus infection considering different stage of liver disease 343 
and determination of the related dosage requirement.   344 
- The simulation of the magnitude of DDIs for first-line drugs used to treat simultaneously 345 
HIV and tuberculosis and/or malaria.  346 
- The simulation of the magnitude of DDIs between antiretroviral agents and anticancer 347 
agents, as such data are difficult to obtain from clinical studies.  348 
It is important to highlight that the accuracy of DDI prediction depends not only on the 349 
PBPK model but also on the data inserted in the model. Detailed investigations may be 350 
required to simulate physiological processes occurring both under normal and pathological 351 
conditions. For instance, it is well known that inflammatory conditions caused by infections 352 
can alter drug disposition processes and thereby impact the magnitude of DDIs69. While 353 
some processes are well characterized, others are poorly described, which may cause the 354 
model to erroneously predict the pharmacokinetics of some drugs. In addition, the inclusion 355 
of drug transporters may improve the prediction of the models to some extent, although 356 
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many challenges remain in this area. For instance, more data are needed to better define the 357 
interplay between CYPs and transporters. Other challenges include the species differences in 358 
the substrate specificity, tissue distribution and relative abundance of drug transporters. 359 
These differences complicate the extrapolation of animal data in humans to quantitatively 360 
predict the impact of transporters on DDIs70. Finally, another area that requires improvement 361 
is the integration of extra-hepatic or non-CYP-related metabolism in the PBPK model to 362 
predict DDIs. 363 
 364 
2.4 Formulations 365 
Many anti-infective drugs are administered orally and are therefore subject to several 366 
environmental factors dictating the extent and rate of oral absorption. These factors can 367 
include pH-dependent solubility, the formation of insoluble complexes with gastrointestinal 368 
contents, instability in the gastrointestinal environment and altered transit time71, 72. To limit 369 
the detrimental effects of these factors, drug formulations can be utilised to control the 370 
release rate of orally-administered drugs in the gastrointestinal lumen, allowing for optimal 371 
absorption. Specialised dosing strategies can include delayed-release formulations, such as 372 
the use of enteric-coated tablets which protect the drug from the acidic environment of the 373 
stomach by preventing dissolution at lower pH73, 74. Extended-release formulations also exist 374 
and are often used to reduce Cmax (decrease host toxicity) and increase the overall exposure 375 
time (improve drug effectiveness)75. Drug absorption into the blood circulatory system 376 
depends upon the delivery of drug particles or solution to the site of absorption. This applies 377 
not only to oral absorption but also to other non-intravenous routes of administration, such as 378 
sub-cutaneous, intra-peritoneal, transdermal, trans-ocular, intra-muscular and pulmonary. 379 
Release of drug from the formulation at these sites will depend on multiple factors, such as 380 
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local pH, tissue fat content and protein constitution. The optimum route of administration for 381 
a drug is often difficult to determine, and PBPK modelling combined with in vitro 382 
experimentation can help predict exposure levels76, 77.  383 
When optimising PBPK models it may be necessary to determine how a formulation interacts 384 
with its environment. Specifically, the drug release rate, the existence of delayed release and 385 
the ability of excipients to alter the properties of the drug or environment are all potential 386 
factors to be integrated. The Advanced Dissolution, Absorption and Metabolism (ADAM) 387 
model was created to take into account the release characteristics of free drug from orally-388 
administered formulations, as well as to include the intestinal metabolism and active transport 389 
of drug78. There are published PBPK models which specifically investigate formulation-390 
dissolution-related issues for anti-infectives. For example, the pH-dependent dissolution rate 391 
of 400 mg film-coated tablets of raltegravir, an anti-HIV integrase inhibitor, was determined 392 
in vitro by our group and subsequently included in a PBPK model to predict the effects of 393 
altered gastrointestinal pH on the rate and extent of drug absorption79. The model predictions 394 
fell within the range of clinical PK profiles and supported previous data showing increased 395 
raltegravir plasma concentrations when co-administered with acid-reducing agents80. 396 
Furthermore, the model in combination with in vitro studies successfully simulated the 397 
reduced oral absorption of raltegravir due to the binding of drug to divalent metals present in 398 
certain antacids81, which has also been observed clinically82. This has led to the design of a 399 
human trial investigating the use of raltegravir with an antacid containing only monovalent 400 
metals, which is unlikely to result in a significant interaction. 401 
 402 
 403 
 404 
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2.5 Penetration in tissues  405 
In many cases a microbial disease can reside in tissues other than the circulatory system, 406 
where sufficient penetration of an anti-infective drug into the target tissue(s) can be essential 407 
for treatment success. The life cycle of the malaria parasite occurs in erythrocytes and 408 
hepatocytes, therefore few potential physiological barriers should exist in achieving high drug 409 
concentrations at these sites83. However, several infections reside in tissues where drug 410 
penetration is more difficult to achieve. Mycobacterium tuberculosis infects macrophages, 411 
which can then migrate to tissues across the body, primarily infecting the lungs but also to 412 
other major organs such as spleen, liver and kidneys84. HIV primarily infects CD4+ T cells 413 
and macrophages which can reside in viral sanctuary sites (locations in the body where 414 
antiretrovirals cannot sufficiently penetrate to prevent viral replication). These sanctuary sites 415 
can include but are not limited to the brain, genital tract, gut-associated lymphoid tissue and 416 
peripheral lymph nodes85. The penetration of drugs in these sites is essential for the complete 417 
inhibition of viral replication in the body. Antifungal drugs are used to treat fungal infections 418 
throughout the body, although tissue distribution of these drugs can vary greatly. For 419 
example, in humans fluconazole showed higher cerebrospinal fluid (CSF) concentrations (52-420 
82% achieved in plasma) than itraconazole (<10% achieved in plasma) which can be 421 
understood by comparing the properties of fluconazole (10% plasma protein binding, log P of 422 
2.17) and itraconazole (98% plasma protein binding, log P of 6.99)86. The brain is often a 423 
target for anti-infectives, but achieving effective drug concentrations at this site may be 424 
impeded by the blood brain barrier (BBB). The BBB is a selective permeation barrier that 425 
separates the extracellular fluid of the brain from the blood circulation87. 426 
In these and other cases, direct measurement of drug concentrations in tissue, rather than in 427 
plasma, may give more meaningful information when linking drug exposure to efficacy88. 428 
However, measuring drug concentrations in human tissue can be impractical, and surrogate 429 
19 
 
animal models are generally regarded as poor predictors of drug tissue distribution in 430 
humans89. A further factor to consider is that some anti-infectives, such as the majority of 431 
antibiotics, require access to the interstitial space fluid (ISF) to elicit an effect, whereas other 432 
anti-infectives, such as all but a couple of anti-HIV drugs, require intracellular access. 433 
Methods using tissue homogenate to determine drug concentrations are therefore unable to 434 
differentiate between drug in ISF and cellular compartments, which may lead to erroneous 435 
predictions90. PBPK modelling provides a useful and flexible strategy to overcome the above 436 
issues. 437 
PBPK models, besides predicting drug plasma exposure, can also simulate the penetration of 438 
drug in individual tissues. Only the free drug in the systemic circulation is assumed to be able 439 
to move from blood into tissues. This process is influenced by the amount of unbound drug in 440 
the plasma (fup) and also by the blood-to-plasma ratio (B:P). Using this approach prior to in 441 
vivo studies, the steady state volume of distribution (Vss) and the affinity of drug for 442 
penetrating each tissue compartment can be estimated using a PBPK model which 443 
incorporates drug-parameters (Log PO:W (i.e. octanol: water), pKa, fup, B:P) with tissue volumes and 444 
composition (fraction of tissue consisting of water, neutral lipids and phospholipids)91. The 445 
general assumption is that a drug with moderately high log P, a lack of charge at 446 
physiological pH, a high fup and a low B:P has favourable characteristics for tissue 447 
penetration. The movement of drug into the tissue is calculated using either perfusion-limited 448 
mechanisms, which assumes an instant ratio is reached in drug concentrations between 449 
flowing blood and corresponding tissue, or permeability-limited mechanisms, where the cell 450 
membrane and interstitial fluid provide additional barriers to drug movement92. The majority 451 
of PBPK models utilise perfusion-limited mechanisms for determining drug distribution, 452 
whereas PBPK models of large hydrophilic drugs and protein often utilise permeation-limited 453 
mechanisms. Each tissue generally has its unique selection and expression levels of drug 454 
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metabolising enzymes (both perfusion-limited and permeation-limited) and drug transporting 455 
proteins (permeation-limited), and this information can be included in PBPK models 456 
provided that these proteins are believed to influence drug disposition. The expression level 457 
and functionality of drug metabolising enzymes and drug transporters can be influenced by 458 
drug-drug interactions, genetics, disease state and other factors discussed elsewhere in the 459 
review, adding further complexities to the accurate prediction of drug tissue penetration.  460 
When a tissue is of particular importance for the efficacy and/or toxicity of a drug, 461 
specialised PBPK models with detailed anatomical sub-compartments can be created. A 462 
PBPK model has been published to predict regional brain PK of acetaminophen in which the 463 
transfer of drug was determined between sub-compartments of CSF, brain extracellular fluid 464 
(ECF) and brain intracellular space (ICS)93. This allowed for the accurate matching of in vivo 465 
data where acetaminophen concentrations were around 4-fold higher in CSF compared to 466 
brain ECF. In specific cases, the interstitial space within tissues can be an important target 467 
site for anti-infective drugs which operate outside the cell, such as for the hydrophilic β-468 
lactam antibiotics and moxifloxacin94-96. As an example, a PBPK model of β-lactam 469 
antibiotics was produced which included both the interstitial and intracellular portions of 470 
tissues. This was shown to have a small but significant effect of drug distribution 471 
calculations94.  472 
 473 
 474 
 475 
 476 
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3. Integration of disease-treatment relationships into PBPK 477 
models: the phenomenon of PBPK/PD modelling 478 
When developing anti-infective drugs it can be crucially important that the pharmacodynamic 479 
characteristics of candidates are accurately assessed and compared, in order to select for lead 480 
candidates. This is usually performed in vitro, with the minimum inhibitory concentration 481 
(MIC) generally being used as a standard measurement for activity of antibiotics and 482 
antifungals. Although the exact definition of MIC can differ depending on disease, for most 483 
antibiotics the MIC is defined as the minimum concentration of drug required to prevent 484 
visible growth of a target organism following 24 hours incubation at 35˚C using standard 485 
inoculums (around 0.5 to 5 million CFU/mL). This method gives no information on the time 486 
course of antibacterial activity or if the activity is bactericidal (kills pathogen) or 487 
bacteriostatic (inhibits pathogen reproduction) in nature, therefore time-kill experiments are 488 
often performed following the determination of MIC. The most common in vitro model used 489 
to assess antibacterial action is the Hollow Fibre model, which uses tubular fibers in a 490 
cartridge through which drug-containing medium is pumped97. Other approaches include 491 
biofilm models and animal infection models98, 99. Once MIC has been established in vitro, the 492 
following PK/PD indices have been found to be useful in estimating in vivo efficacy: 493 
1) T>MIC: the time (T) of exposure of microbe to plasma concentrations exceeding the 494 
MIC. 495 
2) Cmax/MIC: the ratio of maximum plasma concentration (Cmax) to MIC. 496 
3) AUC/MIC: the ratio of area under the the plasma concentration curve (AUC) to MIC. 497 
Antibiotics are generally classed as having an activity which is time-dependent (T>MIC), 498 
concentration-dependent (Cmax/MIC) or dependent on both time of exposure and 499 
concentration (AUC/MIC)100. In contrast to this system, the assessment of antiviral PD is 500 
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often complicated by the fact that in many cases an in vitro screening method does not exist 501 
or is not fully representative of the in vivo situation. Viral replication relies on the 502 
sequestration of host cell machinery, and all viral infections have an intra-cellular component, 503 
which both make developing effective antiviral therapies more difficult. For assessment of 504 
anti-HIV drugs, the reduction in HIV RNA, DNA or protein can be measured in a system 505 
using HIV-infected immortalised or ex vivo CD4+ immunological cells and used to produce 506 
a concentration-efficacy relationship such as EC50 or EC95.  507 
As discussed above, standard PBPK modelling allows for an understanding of factors that 508 
affect the ADME properties of a drug. In addition, information can be included detailing the 509 
efficacy, toxicity and inhibitory/induction potential of a drug101. If a concentration-effect 510 
relationship can also be established, then this allows for the creation of an integrated 511 
PBPK/PD model. The lack of effective in vitro PD screening methods for many infectious 512 
diseases has impeded the widespread use of this system, although there are published 513 
examples which have integrated PD data into compartmental modelling. A simple 2-514 
compartmental PK/PD model was created for the anti-HIV drug bevirimat, where a dose-515 
dependent relationship between drug plasma concentrations and viral load could be used to 516 
predict necessary doses for viral suppression in humans102. A semi-mechanistic PK/PD model 517 
was published by Nielsen et al which assessed the activity of antibacterial agents on 518 
Streptococcus pyogenes103. Time-kill values were determined in vitro for benzylpenicillin, 519 
cefuroxime, erythromycin, moxifloxacin, and vancomycin, and used to create a maximum 520 
effect (Emax) PD model. The natural rate of bacterial growth and death was included, in 521 
addition to drug-induced death. The attached PK model only predicted the chemical 522 
degradation of otherwise static drug concentrations; therefore this model had limited use for 523 
optimisation of antibacterial treatments in patients. An improved PK/PD model was 524 
developed, where a multi-compartment (central and peripheral) system allowed for 525 
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distribution and elimination of the drug, and also allowed for delayed drug action and the 526 
development of drug resistance104, 105.  527 
Physiologically-based parameters were not included in the above mathematical PK models. 528 
As discussed previously, without this information it is not possible to simulate the 529 
distribution of anti-infectives into specific tissues, which are important targets for numerous 530 
diseases residing outside of the circulatory system. As can be seen, important steps have been 531 
made in PK/PD model design, but there are clear benefits to working towards “whole body” 532 
infection models, where the distribution and actions of both the infection and the treatment 533 
can be simulated for optimisation. 534 
 535 
4. Conclusion 536 
The PBPK approach gives the opportunity of integrating in vitro experimental data in a 537 
mathematical description of human anatomy and physiology for the simulation of drug 538 
pharmacokinetics. Overall, this predictive tool can have relevant use for the prediction of 539 
anti-infective pharmacology and efficacy, giving insight of their distribution during the 540 
development process as well as finding application in the simulation of relevant clinical 541 
scenarios (Figure 3). In this review we have described some of the most recent studies 542 
conducted using PBPK, and hypothesised future innovative applications for a more effective 543 
use of anti-infectives not only in the average patients but also for special subpopulations of 544 
infected individuals. There are useful PD models developed using in vitro and in vivo 545 
approaches which can inform PBPK models of “target” concentrations in specific tissues to 546 
achieve treatment success, although much work remains to be done on improving our 547 
knowledge of PK-PD relationships in most diseases. 548 
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 549 
5. Expert opinion 550 
There is an urgent requirement for novel treatment strategies of infectious diseases. The 551 
treatments of many infections remain ineffective and can often result in concentration-552 
dependent host toxicity. Anti-infective resistance development is not a minor concern and 553 
should be acknowledged as a global health crisis, as is emphasised by the current alarming 554 
spread of drug-resistant Mycobacterium tuberculosis and malaria106. Consequently, new 555 
drugs need to be developed which are effective against resistant strains of infection. 556 
Furthermore, in cases where special patient populations have sub-optimal drug exposure due 557 
to alterations in physiology, the pharmacokinetics of currently used anti-infectives should be 558 
improved to prevent drug resistance development. PBPK modelling provides a powerful tool 559 
in our attempts to tackle the above issues, and both industry and regulatory bodies have 560 
recognised the importance of this technology. Between 2008 and 2012, the FDA received 561 
submissions for 18 investigational new drugs (IND) and 16 new drug applications (NDA) 562 
which included PBPK modelling 107. Of these 33 IND/NDA cases, the majority of models 563 
(61%) were used to investigate drug-drug interactions, with the remaining models 564 
investigating paediatrics (18%), absorption (9%), hepatic impairment (6%), 565 
pharmacogenetics (3%) and a combination of pharmacogenetics and drug-drug interactions 566 
(3%). Additionally, the FDA increasingly use PBPK modelling in reviews of clinical 567 
scenarios, with 16 cases recorded between 2009 and 2012. Any definitive measure of model 568 
adequacy for PBPK in clinical pharmacology is yet to be defined and will necessarily vary 569 
from case to case, depending on factors such as the therapeutic window of the investigational 570 
drug. However, the FDA has outlined the essential information of a PBPK analysis needed in 571 
a regulatory submission, and these fundamental questions need to be addressed by the 572 
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applicant (17). Does the model use system- and drug-dependent parameters which are based 573 
on accepted physiology? Have input parameters been produced from reliable and 574 
reproducible data, or, when assumptions are made, can they be justified? Is the model able to 575 
effectively predict existing in vivo data? Does the model contain all necessary parameters to 576 
address known PK-influencing factors for a specific drug? Regarding PBPK modelling of 577 
anti-infectives specifically, many more questions would require to be addressed in specific 578 
cases, and this regulatory assessment of PBPK models is a constantly evolving process. 579 
It should be acknowledged that major challenges remain to be addressed if PBPK modelling 580 
is to be increasingly used in anti-infective research. Diseases can alter the physiological 581 
characteristics of patients, which can in turn change the disposition and effectiveness of anti-582 
infective drugs. To give examples, HIV-infected patients, particularly those with advanced 583 
disease progression, have higher gastric pH than uninfected individuals and this may explain 584 
why acid-reducing agents show reduced impact on the absorption of antiretrovirals with pH-585 
dependent solubility, such as raltegravir, in HIV-infected patients108. Numerous bacterial and 586 
viral infections have been found to alter expression levels of drug metabolising enzymes and 587 
transporters, although the majority of these studies have been performed in animals109. In 588 
reality, for the purposes of constructing PBPK models, an understanding of relevant systems 589 
parameters are lacking in many disease groups and it is essential that pharmacologists, 590 
physiologists and clinicians collaborate to address these knowledge gaps. An extra 591 
complication can arise in the development of fully comprehensive anti-infective PBPK/PD 592 
models in simulated disease groups: most infections would not act as a benign, static factor in 593 
the model. Infection replication and death rates may need to be accounted for, and an 594 
infection may display variability in genetics and phenotype within a “population” which is 595 
relevant for treatment success. Preferences of some infections for specific tissues and the 596 
ability of infectious agents to spread to new locations would complicate the production of 597 
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PK/PD relationships. Furthermore, infections can often exist in different forms during a 598 
lifecycle, some of which show varying sensitivity to treatment, for example in the case of 599 
anti-malarial drugs which are not effective against the life-cycle stage involving the liver. 600 
Investigations into these factors provide great challenges, due to the absence in most cases of 601 
models for determining infection dynamics. However, regarding the establishment of PK/PD 602 
relationships, it is important to aim for simplicity where it is available. In the case of certain 603 
antibiotics, a relatively simple correlation has been established linking PK and PD, as is 604 
detailed in section 3, and this information is easily included in current PBPK model design. 605 
Regarding the future of in silico based “personalised medicine” strategies, the ultimate goal is 606 
to achieve a complete picture incorporating the system of both the specific patient and the 607 
disease, and to combine this with the pharmacodynamics and toxicological characteristics of 608 
the anti-infective. Considering that there is a paucity of information available to construct 609 
these complete PBPK-PD models, a factor to consider is education: in order to attract 610 
researchers to the area of PBPK-PD model development, it is important that users are able to 611 
understand the underlining principals and the science behind modelling. The authors believe 612 
that this learning process should be initiated early in the development of future 613 
pharmacologists, and have included PBPK modelling theory and technique in educational 614 
programs. 615 
 616 
 617 
 618 
 619 
 620 
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Table 1. Main physiological and anatomical changes in special populations and their 621 
potential effect on PK 622 
Special populations Anatomical and physiological factors Potential effect on PK 
Elderly 110, 111 
Increased gastric pH Decreased absorption 
Delayed gastric emptying time 
Slower absorption Decreased splanchnic blood flow 
Decreased gastro-intestinal mobility 
Decreased absorption surface Decreased absorption 
Reduced expression of intestinal enzymes and 
transporters  
Increased absorption 
Increased adiposity 
Higher distribution 
Lower lean body mass and total body water 
Decreased albumin, increased α1-acid-glycoprotein Higher/lower distribution 
Reduced liver weight 
Lower clearance  
Decreased hepatic blood flow 
Changes in the expression of CYP450 isoforms 
Lower/higher clearance 
Changes in plasma protein binding 
Decreased glomerular filtration rate 
Lower clearance 
Decreased kidney mass 
Decreased glomerular surface area 
Decreased renal blood flow 
Obesity 112, 113 
Increase adipose tissue mass Higher distribution 
Increased cardiac output and altered hepatic blood 
flow 
Higher distribution and 
higher/lower clearance 
Increased glomerular filtration and tubular secretion Higher clearance 
Altered expression of metabolic enzymes  Higher/lower clearance 
Pregnancy  114 
Increased cardiac output Higher distribution and 
higher clearance 
Increase adipose tissue mass 
Higher distribution Increased total body water 
Increased plasma volume 
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Decreased plasma protein levels Altered protein binding 
Altered expression of metabolic enzymes Higher/lower clearance 
 623 
 624 
Article highlight box 625 
 626 
• The pharmacokinetic and pharmacodynamic properties of anti-infective drugs are 627 
often not fully understood but are usually found to relate to treatment success, and the 628 
development of new and improved anti-infective agents is essential if improvements 629 
in current disease treatment, including the treatment of drug-resistant infectious 630 
strains, are to be achieved. 631 
• The optimisation of anti-infective drugs in special populations, such as paediatrics, 632 
the elderly, pregnant patients and patients who have co-morbidities, is difficult due to 633 
small group sizes and the additional risks associated with experimental treatment.   634 
• Physiologically based pharmacokinetic modelling is a useful tool which allows for the 635 
creation of “virtual” populations with defined physiological characteristics and 636 
variability, which can then be combined with the physicochemical and biological 637 
properties of a drug to simulate drug pharmacokinetic pharmacodynamic 638 
characteristics. 639 
• Models can be designed which investigate how drug disposition in the human body is 640 
influenced by factors such as genetics, drug-drug interactions, formulation properties, 641 
and drug disposition when simulated in special population. 642 
• Physiologically based pharmacokinetic modelling can be combined with the 643 
pharmacodynamic properties of an anti-infective agent in order to fully predict the 644 
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interaction between the drug and infectious agent in an in vivo situation, allowing for 645 
the simulation of treatment effectiveness. 646 
• Many areas remain where further research is required to improve the predictive value 647 
of physiologically based pharmacokinetic modelling of anti-infectives, including 648 
establishing improved correlations between in vitro and in vivo anti-infective 649 
pharmacodynamic relationships, and increasing our understanding of physiological 650 
changes occurring in patients during disease progression. 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
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